IF MDI-2517, a selective small-molecule Plasminogen Activator Inhibitor-1 (PAI-1) inhibitor, is administered systemically (orally via daily gavage) to naturally aged (20-24 month-old) C57BL/6J mice for 12 weeks,

THEN a simultaneous, multi-organ reversal of established extracellular matrix (ECM) fibrosis (measured by >30% reduction in tissue hydroxyproline and Masson's trichrome collagen proportional area) and clearance of senescent cell burden (measured by reduced SA-$\beta$-gal and p16INK4a expression) will be observed across the liver, lung, and kidney,

BECAUSE:

1. Pathological PAI-1 is chronically upregulated in aged tissues as a core, active driver of the Senescence-Associated Secretory Phenotype (SASP), where it maintains senescent cell viability via anti-apoptotic PI3K/Akt signaling (PAI-1 maintains the senescent state by inhibiting apoptosis)["PAI-1, a target for aging and age-related diseases", Aging Cell].
2. Systemic pharmacological inhibition of PAI-1 disrupts this autocrine survival loop, stripping senescent cells of their apoptosis resistance and acting as a senolytic/senomorphic adjuvant to clear death-resistant cells (Neutralizing PAI-1 directly suppresses transcription of SASP factors)["A null mutation in SERPINE1 protects against biological aging in humans", Science Advances].
3. Concurrently, PAI-1 inhibition disinhibits tissue-type (tPA) and urokinase-type (uPA) plasminogen activators, restoring local plasmin generation in fibrotic tissues (Plasminogen activation system regulates ECM homeostasis)["Targeting the plasminogen activation system in disease", Nature Reviews Drug Discovery].
4. [SPECULATIVE] Restored active plasmin directly proteolyzes pathological fibrin deposits and activates latent matrix metalloproteinases (MMP-1, -3, and -9), driving the targeted degradation of already-accumulated cross-linked collagen scars across independent organ systems simultaneously (Plasmin activates latent MMPs to drive ECM degradation)["Plasminogen activator inhibitor-1 and the pathogenesis of fibrosis", Journal of Clinical Investigation].

One-liner: Systemic PAI-1 inhibition with MDI-2517 acts as a dual-action gerotherapeutic, simultaneously clearing senescence-associated death-resistant cells (ApoptoSENS) and triggering plasmin-mediated enzymatic degradation of multi-organ fibrotic scars (GlycoSENS).

SENS category: GlycoSENS